Schrodinger Inc

Latest Results (15.08.2026):

Schrödinger Inc — Second Quarter 2026: the company reported ACV of $29.6 million (27% year‑over‑year), total revenue of $58.9 million (up 8% YoY) and GAAP net income of $6.0 million versus a loss the prior year. Results were boosted by a $10 million collaboration milestone tied to the Ajax Therapeutics acquisition and a $48.9 million other‑income gain related to Eli Lilly’s completion of that acquisition. Schrödinger also launched early access to its agentic AI co‑scientist “Bunsen,” secured strategic cloud/AI partners and raised its drug discovery revenue outlook for 2026.

ACV and revenue mix

Annual Contract Value (ACV) was $29.6M in Q2 2026 (27% growth) and $208M on a trailing four‑quarter basis; ACV excluding contribution ACV was $22.6M (23% growth). Total revenue was $58.9M: software $32.5M (down 10% YoY, reflecting hosted licensing transition) and drug discovery $23.0M (up, driven by a $10M Ajax milestone). Contribution revenue was $3.4M.

Profitability drivers

GAAP net income was $6.0M (vs a $43.2M loss in Q2 2025). This swing was largely driven by $48.9M of other income (change in fair value / gain associated with Eli Lilly’s Ajax acquisition). Operating loss from core operations remained $(41.5)M for the quarter. Adjusted EBITDA was negative (company reported a three‑month adjusted EBITDA of $(31.0)M).

Margins and operating expenses

Software gross margin was 71%. Total operating expenses were $74.0M, a 6% decrease YoY (R&D $41.0M, S&M $10.3M, G&A $22.7M), reflecting modest cost control amid continued investment.

Balance sheet and cash

As of June 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled about $418.8M. Total assets were $640.4M and total stockholders’ equity was $329.0M.

Guidance (2026 outlook)

For the fiscal year ending Dec 31, 2026, Schrödinger expects ACV of $218–228M (10–15% growth vs 2025), raised drug discovery revenue guidance to $65–75M (from prior $55–65M) reflecting the Ajax milestone, and expects operating expenses to be lower than in 2025. Q3 2026 ACV guidance (excluding contribution ACV) is $41–45M.

Products, partnerships and commercial traction

Schrödinger launched early access to Bunsen, an agentic AI co‑scientist designed to scale physics‑based workflows, and announced strategic cloud/AI support from NVIDIA and Google Cloud. The company secured a software agreement to deploy Bunsen at Bristol Myers Squibb and announced a drug discovery collaboration with Simcere. Published validation studies also reinforced the company’s platform capability.